FDA expands approval of treatment for cystic fibrosis to include patients ages 6 and olderJune 21, 2019
HHS Secretary Statement on Ninth Circuit’s Rejection of Nationwide Block on New Family Planning PolicyJune 20, 2019
Statement on a new effort to improve transparency and predictability for generic drug applicants to help increase timely access to high-quality, lower cost generic drugsJune 18, 2019
Statement on new guidance for the declaration of added sugars on food labels for single-ingredient sugars and syrups and certain cranberry productsJune 18, 2019
Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on latest steps to strengthen FDA’s 510(k) program for premarket review of medical devicesJune 15, 2019
FDA Statement on the FDA’s ongoing investigation into valsartan and ARB class impurities and the agency’s steps to address the root causes of the safety issuesJune 15, 2019
Federal officials seize adulterated dietary supplements from Life Rising Corporation due to poor manufacturing practicesJune 14, 2019
U.S. Departments of Health and Human Services, Labor, and the Treasury Expand Access to Quality, Affordable Health Coverage Through Health Reimbursement ArrangementsJune 13, 2019
Statement on FDA’s scientific work to understand per- and polyfluoroalkyl substances (PFAS) in food, and findings from recent FDA surveysJune 11, 2019
FDA finalizes guidance for premarket tobacco product applications for electronic nicotine delivery systems as part of commitment to continuing a strong oversight of e-cigarettesJune 11, 2019
FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphomaJune 10, 2019
FDA permits marketing of first medical device for relief of pain associated with irritable bowel syndrome in patients 11-18 years of ageJune 7, 2019
